Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
about
Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literatureEpstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer".Prognostic significance of tumor volume in locally recurrent nasopharyngeal carcinoma treated with salvage intensity-modulated radiotherapyCorrelates of anti-EBV EBNA1 IgA positivity among unaffected relatives from nasopharyngeal carcinoma multiplex families.Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study.Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.Invited commentary: Epstein-Barr virus-based screening for the early detection of nasopharyngeal carcinoma: a new frontier.High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.iTRAQ-Based Quantitative Proteomic Analysis of Nasopharyngeal Carcinoma.Radiosensitization effect of nedaplatin on nasopharyngeal carcinoma cells in different status of Epstein-Barr virus infection.The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects.The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma.Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.The incidence and prognosis of nasopharyngeal carcinoma patients with family history.Epstein-Barr virus association with peptic ulcer disease.
P2860
Q27021572-5329197D-316F-42EB-B6F8-FEDE1BE91A77Q33847952-893B16F0-2183-4E02-82F2-E40B0D05BF18Q35232552-5FC34C54-87C0-4AA8-A91C-3F24DEB1363DQ35558480-E2BCB81D-A926-4DE8-BDB8-D0C1F6B9A568Q35653755-8210C93C-3FCB-44D7-9D7A-764A640D2246Q35717112-3A36DDD0-3E80-4C21-8C36-00D1C3D76272Q36557221-03A99E40-459B-44C0-A2C5-D425DB2D7C1BQ36764940-430E9AEB-729F-45F5-BF74-03520E926DAEQ37100066-5D6C7FCC-6175-484C-9770-E58144B9BBCDQ38913291-C85F9088-F810-43CA-8C22-75A99616DA75Q38988048-FF42CA91-B7ED-4541-A9E3-730D6C85B050Q39609423-E4F39AC8-2A25-4850-B46A-75229D0C1C39Q40770021-F56827AA-004A-48ED-81A4-EBEA4EC022CEQ47106227-7A49C543-1ECB-428D-B813-F639B750DB6CQ47195737-98700F53-F60F-4129-AADA-E33399D135C6Q50991183-B0B13172-2E81-46C0-83C2-1A9967916B00
P2860
Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Prognostic utility of anti-EBV ...... s from high-risk NPC families.
@ast
Prognostic utility of anti-EBV ...... s from high-risk NPC families.
@en
type
label
Prognostic utility of anti-EBV ...... s from high-risk NPC families.
@ast
Prognostic utility of anti-EBV ...... s from high-risk NPC families.
@en
prefLabel
Prognostic utility of anti-EBV ...... s from high-risk NPC families.
@ast
Prognostic utility of anti-EBV ...... s from high-risk NPC families.
@en
P2093
P2860
P50
P1476
Prognostic utility of anti-EBV ...... ls from high-risk NPC families
@en
P2093
Alisa M Goldstein
Allan Hildesheim
Chien-Jen Chen
Kelly J Yu
Patti Gravitt
Ruth M Pfeiffer
Scott R Diehl
Wan-Lun Hsu
Yu-Juen Cheng
P2860
P304
P356
10.1158/1078-0432.CCR-10-1681
P407
P577
2011-03-29T00:00:00Z